CNSYNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
CERENOME, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.65−0.05 (-2.94%)
Close on Oct 19, 2026
- Market cap
- $11.38M
- P/E (TTM)
- –
- Dividend yield
- –
CERENOME, INC. revenue by segment
By business segment
By product or service
| Revenue | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | TTM Q4 22 | TTM Q4 18 | TTM Q1 18 | TTM Q4 17 | TTM Q3 17 | TTM Q2 17 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grant [Member] | $5.73M | $5.51M | $6.08M | $4.91M | $3.75M | $2.58M | $224.00K | – | – | – | – | – | 100.0% | +52.6% |
| Consumable [Member] | – | – | – | – | – | – | – | $2.17M | $1.97M | $1.92M | – | – | – | – |
| Device [Member] | – | – | – | – | – | – | – | $225.00K | $640.00K | $576.00K | – | – | – | – |
| Other Products [Member] | – | – | – | – | – | – | – | $277.00K | $221.00K | $195.00K | – | – | – | – |
By region
| Revenue | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | TTM Q4 22 | TTM Q4 18 | TTM Q1 18 | TTM Q4 17 | TTM Q3 17 | TTM Q2 17 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Japan | – | – | – | – | – | – | – | $2.06M | $2.18M | $1.92M | $2.48M | $2.78M | – | – |
| Americas [Member] | – | – | – | – | – | – | – | $293.00K | $242.00K | $345.00K | $581.00K | $548.00K | – | – |
| Asia Pacific [Member] | – | – | – | – | – | – | – | $50.00K | $83.00K | $76.00K | $129.00K | $72.00K | – | – |
| EMEA [Member] | – | – | – | – | – | – | – | $270.00K | $322.00K | $344.00K | $302.00K | $360.00K | – | – |
From the segment and revenue-disaggregation notes of Cerenome's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.